# Altimmune, Inc. clinical trials: 20 (November 2026)

Updated November 19, 2026.

ClinicalTrials.gov lists 20 trials with Altimmune, Inc. as lead sponsor, 1 of them recruiting or not yet recruiting, as read on November 19, 2026.

## The full list

Clinical trials led by Altimmune, Inc.: 20 rows for $5, every trial on ClinicalTrials.gov as read on November 19, 2026. Columns: NCT ID, Title, Sponsor, Sponsor class, Phase, Status, Conditions, Condition groups (MeSH), Interventions, Start date, First posted, Last update posted, Enrollment, Location countries, Read on, Source. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (sponsor class, condition groups (MeSH), interventions, start date, last update posted and location countries), which open on your screen as soon as the payment clears and come by email.

Buy: https://specstream.ai/data/clinical-trials/company/altimmune-inc

SpecStream is the live web data engine for teams and agents. It reads ClinicalTrials.gov each morning, and this page is that reading. Ask for the sponsors, conditions, phases or places you follow and each new or changed trial arrives in your sheet, CRM, Slack or agent with the sponsor, phase, status and sites.

- Trials: 20
- Recruiting or not yet: 1
- Read on: November 19, 2026

## Trials

The 20 newest of 20, each linked to its ClinicalTrials.gov record. The full list holds every one.

| First posted | NCT ID | Title | Sponsor | Phase | Status | Conditions | Enrollment | Source |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| August 31, 2026 | NCT07795164 | Phase 3 Study of the Efficacy, Safety, and Clinical Outcomes of Pemvidutide in MASH | Altimmune, Inc. | Phase 3 | Recruiting | Metabolic Dysfunction-Associated Steatohepatitis (MASH) | 1,800 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07795164) |
| June 8, 2025 | NCT07009860 | RESTORE TRIAL: Study of the Efficacy and Safety of Pemvidutide in the Treatment of Alcohol-Associated Liver Disease (ALD) | Altimmune, Inc. | Phase 2 | Active not recruiting | Alcohol-associated Liver Disease | 121 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07009860) |
| May 23, 2025 | NCT06987513 | RECLAIM STUDY: Phase 2 Study of the Efficacy and Safety of Pemvidutide in the Treatment of Alcohol Use Disorder (AUD) in Subjects With... | Altimmune, Inc. | Phase 2 | Completed | Alcohol Use Disorder (AUD) | 100 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06987513) |
| August 14, 2023 | NCT05989711 | IMPACT TRIAL: Efficacy and Safety of Pemvidutide in Subjects With Nonalcoholic Steatohepatitis (NASH) | Altimmune, Inc. | Phase 2 | Completed | Non-Alcoholic Steatohepatitis (NASH) | 212 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05989711) |
| March 25, 2022 | NCT05295875 | Efficacy and Safety of ALT-801 in the Treatment of Obesity | Altimmune, Inc. | Phase 2 | Completed | Obesity/Overweight | 391 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05295875) |
| March 23, 2022 | NCT05292911 | Extension of ALT-801 in Diabetic and Non-Diabetic Overweight and Obese Subjects With (NAFLD) | Altimmune, Inc. | Phase 1 | Completed | Non-Alcoholic Fatty Liver Disease | 64 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05292911) |
| November 26, 2021 | NCT05134662 | ALT-801 in Overweight and Obese Subjects With Type 2 Diabetes Mellitus (T2DM) | Altimmune, Inc. | Phase 1 | Completed | Type 2 Diabetes | 55 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05134662) |
| August 16, 2021 | NCT05006885 | ALT-801 in Diabetic and Non-Diabetic Overweight and Obese Subjects With Non-alcoholic Fatty Liver Disease (NAFLD) | Altimmune, Inc. | Phase 1 | Completed | Non-Alcoholic Fatty Liver Disease | 95 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05006885) |
| July 22, 2021 | NCT04972396 | Pemvidutide (ALT-801) DDI Study in Healthy Volunteers | Altimmune, Inc. | Phase 1 | Completed | NASH - Nonalcoholic Steatohepatitis | 40 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04972396) |
| December 28, 2020 | NCT04684914 | HepTcell Immunotherapy in Patients With Inactive Chronic Hepatitis B (CHB) | Altimmune, Inc. | Phase 2 | Terminated | Hepatitis B, Chronic | 87 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04684914) |
| December 22, 2020 | NCT04679909 | Safety and Immunogenicity of AdCOVID in Healthy Adults (COVID-19 Vaccine Study) | Altimmune, Inc. | Phase 1 | Completed | Healthy Volunteers | 92 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04679909) |
| September 23, 2020 | NCT04561245 | ALT-801 (Pemvidutide) in Healthy Overweight and Obese Volunteers to Study Safety and Tolerability | Altimmune, Inc. | Phase 1 | Completed | Obesity, Nonalcoholic Steatohepatitis | 100 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04561245) |
| June 22, 2020 | NCT04442230 | NasoVAX in Patients With Early Coronavirus Infectious Disease 2019 (COVID-19) | Altimmune, Inc. | Phase 2 | Terminated | Coronavirus Infection | 48 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04442230) |
| June 4, 2020 | NCT04415749 | NasoShield in Healthy Adults to Study Safety and Immunogenicity | Altimmune, Inc. | Phase 1 | Completed | Healthy Volunteers | 43 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04415749) |
| November 30, 2018 | NCT03760549 | Study of the Safety and Immunogenicity of NasoVAX Extension | Altimmune, Inc. | Observational | Completed | Influenza | 8 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03760549) |
| November 24, 2017 | NCT03352466 | NasoShield Study of Safety and Immunogenicity | Altimmune, Inc. | Phase 1 | Completed | Healthy Volunteers | 145 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03352466) |
| July 28, 2017 | NCT03232567 | Single-ascending-dose Study of the Safety and Immunogenicity of NasoVAX | Altimmune, Inc. | Phase 2 | Completed | Influenza | 60 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03232567) |
| May 23, 2017 | NCT03163342 | Immune Response Following Seasonal Influenza Vaccination | Altimmune, Inc. | Phase 4 | Completed | Influenza | 20 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03163342) |
| July 14, 2015 | NCT02496897 | Phase I Safety and Immunogenicity of FP-02.2 in Chronic Hepatitis B | Altimmune, Inc. | Phase 1 | Completed | Hepatitis B | 61 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02496897) |
| September 19, 2008 | NCT00755703 | Safety and Immunogenicity Study of Adenovirus-vectored, Intranasal Pandemic Influenza Vaccine. | Altimmune, Inc. | Phase 1 | Completed | Influenza A Subtype H5N1 Infection | 48 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT00755703) |

## By phase

| Phase | Trials |
| --- | --- |
| Phase 1 | 10 |
| Phase 2 | 7 |
| Phase 3 | 1 |
| Phase 4 | 1 |
| Observational | 1 |

## By status

| Status | Trials |
| --- | --- |
| Completed | 16 |
| Terminated | 2 |
| Active not recruiting | 1 |
| Recruiting | 1 |

## Conditions

| Condition group | Trials |
| --- | --- |
| Obesity | 6 |
| Non-alcoholic Fatty Liver Disease | 5 |
| Overweight | 5 |
| Influenza, Human | 4 |
| COVID-19 | 2 |
| Anthrax | 2 |
| Hepatitis B, Chronic | 1 |
| Influenza in Birds | 1 |
| Alcoholism | 1 |
| Hepatitis B | 1 |
| Coronavirus Infections | 1 |
| Diabetes Mellitus, Type 2 | 1 |

## Where the register publishes

- [ClinicalTrials.gov](https://clinicaltrials.gov/)
- [ClinicalTrials.gov API](https://clinicaltrials.gov/data-api/api)

Source: [ClinicalTrials.gov API v2 (U.S. National Library of Medicine)](https://clinicaltrials.gov/data-api/api). U.S. government data; ClinicalTrials.gov terms of use. Studies are as their sponsors registered them on ClinicalTrials.gov, read through its API. Recruiting means the record's overall status is recruiting or not yet recruiting. Condition groups are the MeSH terms ClinicalTrials.gov assigns; a condition page also counts the narrower terms that name it, as the register's own search does (triple negative breast neoplasms are breast neoplasms). Sites are shown as organizations only; no investigator or contact is read or shown.

Free to quote with credit and a link. Copying in bulk needs a [data licence](https://specstream.ai/data/licence).

## Business lists in the United States

- [TV service providers in the United States](https://specstream.ai/data/businesses/tv-service-providers/united-states)
- [Pan Asian restaurants in the United States](https://specstream.ai/data/businesses/pan-asian-restaurants/united-states)
- [Generator installation repair companies in the United States](https://specstream.ai/data/businesses/generator-installation-repair-companies/united-states)
- [Burmese restaurants in the United States](https://specstream.ai/data/businesses/burmese-restaurants/united-states)
- [Thai restaurants in the United States](https://specstream.ai/data/businesses/thai-restaurants/united-states)
- [Nursing services in the United States](https://specstream.ai/data/businesses/nursing-services/united-states)
